crestor rosuvastatin (as calcium) 20mg tablet blister pack
a menarini australia pty ltd - rosuvastatin calcium, quantity: 20.8 mg - tablet, film coated - excipient ingredients: iron oxide red; lactose monohydrate; magnesium stearate; triacetin; hypromellose; calcium phosphate; crospovidone; titanium dioxide; microcrystalline cellulose - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,crestor is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease).,crestor is indicated to: = reduce the risk of nonfatal myocardial infarction = reduce the risk of nonfatal stroke. = reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: crestor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with crestor , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
crestor rosuvastatin (as calcium) 10mg tablet blister pack
a menarini australia pty ltd - rosuvastatin calcium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: magnesium stearate; titanium dioxide; hypromellose; crospovidone; iron oxide red; lactose monohydrate; calcium phosphate; triacetin; microcrystalline cellulose - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,crestor is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease).,crestor is indicated to: = reduce the risk of nonfatal myocardial infarction = reduce the risk of nonfatal stroke. = reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: crestor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with crestor , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
crestor rosuvastatin (as calcium) 5mg tablet blister pack
a menarini australia pty ltd - rosuvastatin calcium, quantity: 5.2 mg - tablet, film coated - excipient ingredients: iron oxide yellow; microcrystalline cellulose; titanium dioxide; crospovidone; calcium phosphate; lactose monohydrate; magnesium stearate; triacetin; hypromellose - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,crestor is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease).,crestor is indicated to: = reduce the risk of nonfatal myocardial infarction = reduce the risk of nonfatal stroke. = reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: crestor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with crestor , secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
crestor 5 mg film-coated tablets
astrazeneca ab - rosuvastatin - film-coated tablet - 5 milligram(s) - hmg coa reductase inhibitors; rosuvastatin
crestor 10 mg film-coated tablets
astrazeneca ab - rosuvastatin - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; rosuvastatin
crestor 20 mg film-coated tablets
astrazeneca ab - rosuvastatin - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; rosuvastatin
crestor 40 mg film-coated tablets
astrazeneca ab - rosuvastatin - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; rosuvastatin
rosuvastatin 10 mg film-coated tablets
accord healthcare ireland ltd. - rosuvastatin calcium - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; rosuvastatin
rosuvastatin 20 mg film-coated tablets
accord healthcare ireland ltd. - rosuvastatin calcium - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; rosuvastatin
rosuvastatin 40 mg film-coated tablets
accord healthcare ireland ltd. - rosuvastatin calcium - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; rosuvastatin